Gary Nachman
Stock Analyst at Raymond James
(3.01)
# 1,459
Out of 4,996 analysts
95
Total ratings
60.87%
Success rate
5.84%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Assumes: Market Perform | n/a | $272.98 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $3.73 | +436.19% | 2 | Aug 13, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $227 → $236 | $220.61 | +6.98% | 16 | Aug 1, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Outperform | $39 → $40 | $42.03 | -4.83% | 2 | Jul 31, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Strong Buy | $60 → $64 | $64.09 | -0.14% | 3 | Jul 31, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.30 | +45.08% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $446.40 | -33.24% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.01 | +564.45% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $25.24 | +46.59% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $14.50 | +31.03% | 1 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $38.75 | -22.58% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $5.99 | +16.86% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $127.00 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $9.75 | -58.97% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $11.78 | +154.67% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.74 | +575.11% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $9.52 | +47.06% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $18.34 | -45.47% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $28.63 | +4.79% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.33 | +22,422.52% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.48 | +23.46% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $26.84 | -21.76% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $5.65 | +147.79% | 2 | Jun 14, 2018 |
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $272.98
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $3.73
Upside: +436.19%
AbbVie
Aug 1, 2025
Maintains: Outperform
Price Target: $227 → $236
Current: $220.61
Upside: +6.98%
LENZ Therapeutics
Jul 31, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $42.03
Upside: -4.83%
Ionis Pharmaceuticals
Jul 31, 2025
Maintains: Strong Buy
Price Target: $60 → $64
Current: $64.09
Upside: -0.14%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.30
Upside: +45.08%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $446.40
Upside: -33.24%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.01
Upside: +564.45%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.24
Upside: +46.59%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $14.50
Upside: +31.03%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $38.75
Upside: -22.58%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $5.99
Upside: +16.86%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $127.00
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $9.75
Upside: -58.97%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $11.78
Upside: +154.67%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.74
Upside: +575.11%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $9.52
Upside: +47.06%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $18.34
Upside: -45.47%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $28.63
Upside: +4.79%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.33
Upside: +22,422.52%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.48
Upside: +23.46%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $26.84
Upside: -21.76%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $5.65
Upside: +147.79%